|By PR Newswire||
|September 1, 2014 10:58 AM EDT||
DUBLIN, Sept. 1, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the " Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014" report to their offering.
This report is a comprehensive analysis and market study of new developments relating to early-stage minimally-invasive biomarkers in Alzheimer's disease, which have been 'functionally reviewed' alongside existing AD drugs and candidates in the AD drug pipeline, and applicable commercial AD diagnostics.
New advances have been made in the discovery and validation of biomarkers in Alzheimer's disease (AD), offering much-needed opportunities to accelerate disease research, drug discovery and the development of low-cost minimally-invasive tests that will be available to much wider patient populations.
This report gives a comprehensive and up-to-date analysis of new findings relating to the discovery and clinical evaluation of AD-related biomarkers with potential to allow early detection or progression of this disease, based on minimally-invasive or non-invasive methods. With a focus on controlled human studies of AD, these biomarker findings are 'functionally reviewed' alongside drugs and drug candidates in the development pipeline, and a market analysis of applicable (minimally-invasive) AD-related diagnostics tests, platforms and developments. This report also includes an analysis of related opportunities in AD research, drug discovery, clinical trials and clinical diagnostics.
Key Topics Covered:
Chapter 1. Background
Chapter 2. Blood Biomarkers
Chapter 3. Autoantibodies
Chapter 4. Urinary Biomarkers
Chapter 5. Salivary Biomarkers
Chapter 6. Other Biomarkers
Chapter 7. AD Drug Pipeline
Chapter 8. Diagnostics Companies of Minimally-Invasive AD Diagnostics
Chapter 9. An Integrated Analysis of AD Biomarkers
Chapter 10. Conclusions and Opportunities
For more information visit http://www.researchandmarkets.com/research/mh4stv/_earlystage
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
Oct. 1, 2016 11:30 AM EDT Reads: 1,322
Oct. 1, 2016 11:15 AM EDT Reads: 867
Oct. 1, 2016 10:45 AM EDT Reads: 601
Oct. 1, 2016 10:30 AM EDT Reads: 1,724
Oct. 1, 2016 10:30 AM EDT Reads: 710
Oct. 1, 2016 10:00 AM EDT Reads: 518
Oct. 1, 2016 10:00 AM EDT Reads: 3,319
Oct. 1, 2016 10:00 AM EDT Reads: 3,197
Oct. 1, 2016 10:00 AM EDT Reads: 605
Oct. 1, 2016 10:00 AM EDT Reads: 4,672
Oct. 1, 2016 09:45 AM EDT Reads: 834
Oct. 1, 2016 09:45 AM EDT Reads: 2,768
Oct. 1, 2016 09:15 AM EDT Reads: 1,677
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
Oct. 1, 2016 09:00 AM EDT Reads: 2,944